What is HPTN 083-01?
PrEP is medicine given to prevent Human Immunodeficiency Virus (HIV) infection before it occurs. Cabotegravir is a new drug that has been found to be effective at preventing HIV among adults.
HPTN 083-01 is a study to find out if long-acting, injectable cabotegravir (CAB LA) for PrEP (pre-exposure prophylaxis) is safe and acceptable to use in adolescents.
St. Jude is one of four sites participating in the study. Denver, Chicago and Boston are the other study sites. The study will enroll a total of 50 participants at all locations.
Who is eligible for the HPTN 083-01 study?
You may be eligible for this study if:
- You are 17 years old or younger
- You do not have HIV
- You were assigned male at birth
- You have had or are interested in sexual experiences with male or transgender partners
Why is the study important?
More than 20% of new HIV infections occur among young people ages 13 to 24. PrEP medicine is an effective way to prevent HIV infection in at-risk adolescents and adults.
Only two PrEP medicines are currently approved by the U.S. Food and Drug Administration. Both of these medicines are taken as pills. A long-acting, injectable form of PrEP, such as cabotegravir, could give at-risk individuals another preventive option.
If you have questions about the HPTN 083-01 study or want to talk with someone about participating, call or text the study staff at 901-216-1166 or email firstname.lastname@example.org.
To confirm eligibility, complete the pre-screening questionnaire and the study staff will contact you.
Review Frequently Asked Questions about the HPTN083-01 study.
Read about the St. Jude HIV Prevention Program.